Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, dedicated to producing biologic active ingredients for Alzheimer's treatments. Additionally, Lilly unveiled a new $800 million facility in Kinsale, Ireland, operational since last year to meet the high demand for diabetes and obesity medications. This expansion is part of a larger $20 billion investment plan initiated since 2020.
The Limerick site will employ 450 highly skilled workers and utilize advanced technologies such as AI and machine learning. Production is expected to start in 2026, pending planning approval. The Kinsale facility integrates continuous manufacturing technology and recently won the 'Facility of the Year' Innovation award.
Lilly emphasizes sustainability, with the Limerick site designed to reduce energy, water, and waste, and the Kinsale site powered by the largest privately owned solar farm in Ireland.
Positive
- Lilly announced a $1 billion expansion in Limerick, increasing its total investment to $2 billion.
- The $800 million Kinsale facility began making medicines last year to meet significant demand.
- Limerick site will create 150 new jobs, total employment reaching 450.
- Lilly has committed over $20 billion for global manufacturing expansion since 2020.
- Limerick site will employ advanced technologies like AI, enhancing production efficiency.
- Kinsale facility won 'Facility of the Year' Innovation award.
- Limerick site will operate with 35% lower energy intensity, 40% less water use, and 15% less waste.
Negative
- None.
News Market Reaction – LLY
In the trading session that priced this news, LLY gained 1.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company ups manufacturing investment in Limerick by
New investment will enhance global medicine production, benefiting millions of patients worldwide
This additional investment is part of the most ambitious manufacturing expansion agenda in the company's history. Since 2020, Lilly has committed more than
"These investments will boost the production of some of our medicines, helping millions of people with diabetes, obesity and Alzheimer's disease live the healthiest lives possible," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. "We won't stop there – these state-of-the-art facilities will also be equipped to support our promising pipeline molecules of the future."
Limerick,
Once complete, Limerick will join Lilly's global manufacturing network producing the biologic active ingredients for the company's Alzheimer's disease portfolio and other biologic medicines.
"Alzheimer's disease is a devastating diagnosis for both the patient and for their loved ones, along with having a huge burden on society," said Anne E. White, executive vice president and president of Lilly Neuroscience. "The treatments we will make here in Limerick offer the potential to be able to slow the progression of the disease and make life better for millions of people around the world."
Today's announcement brings Lilly's total Limerick investment to
The Limerick investment project is subject to planning approval, and the company will submit a planning application to the Limerick City and County Council in due course.
Kinsale,
Lilly remains dedicated to addressing major global health issues, and the Kinsale facility is pivotal to maintaining the safe and reliable supply of Lilly's diabetes and obesity medications. The official opening of Lilly's Kinsale manufacturing site expansion marks the completion of the state-of-the-art project to help meet the demand for current and future treatments. The site employs a digital-first process that integrates continuous manufacturing technology to create a new manufacturing platform for creating complex peptides. This facility was recently recognized as the winner of the Innovation category in the prestigious "Facility of the Year" awards program run by the International Society of Pharmaceutical Engineers.
Sustainability
Lilly has a long-standing commitment to sustainability and respecting the local environment, establishing environmental programs across all sites in
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. C-LLY
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about planned capital investments in manufacturing sites and reflects Lilly's current beliefs and expectations. There are substantial risks and uncertainties in the manufacturing process, development, and commercialization of pharmaceutical products which could impact the overall commercial success of our products. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: | Carla Cox; cox_carla@lilly.com; +1 317-750-3923 |
Joe Fletcher; jfletcher@lilly.com; +1 317-296-2884 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-expands-manufacturing-footprint-in-ireland-with-1-8-billion-investment-302245823.html
SOURCE Eli Lilly and Company